Literature DB >> 12667887

Altered states: the clinical effects of Ecstasy.

J C Cole1, H R Sumnall.   

Abstract

Ecstasy is the second most widely abused illegal drug in Europe. Ecstasy is the colloquial name for 3,4-methylenedioxymethamphetamine (MDMA), but not all Ecstasy tablets contain MDMA. When taken in hot, crowded environments, Ecstasy/MDMA users have developed acute complications that have had fatal consequences. Epidemiological evidence indicates that adverse reactions to Ecstasy/MDMA intoxication are rare and idiosyncratic. Potential mechanisms of action are reviewed. In animal studies, MDMA damages serotonergic fibres and reduces the number of serotonin transporter sites within the CNS. Demonstration of neurotoxicity in human users of Ecstasy is hampered by a number of confounds that the majority of published studies have failed to address. These confounds are reviewed and their impact is discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12667887     DOI: 10.1016/s0163-7258(03)00003-2

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  30 in total

Review 1.  Hallucinogens: an update.

Authors:  John H Halpern
Journal:  Curr Psychiatry Rep       Date:  2003-10       Impact factor: 5.285

2.  21-year-old woman with palpitations and vomiting.

Authors:  Peter P Stanich; Paul S Mueller
Journal:  Mayo Clin Proc       Date:  2010-09       Impact factor: 7.616

3.  MDMA (Ecstasy) use and psychiatric problems.

Authors:  Casey R Guillot; Mitchell E Berman
Journal:  Psychopharmacology (Berl)       Date:  2006-10-24       Impact factor: 4.530

Review 4.  The preclinical pharmacology of mephedrone; not just MDMA by another name.

Authors:  A R Green; M V King; S E Shortall; K C F Fone
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

Review 5.  Contributions of nonhematopoietic cells and mediators to immune responses: implications for immunotoxicology.

Authors:  Barbara L F Kaplan; Jinze Li; John J LaPres; Stephen B Pruett; Peer W F Karmaus
Journal:  Toxicol Sci       Date:  2015-06       Impact factor: 4.849

Review 6.  The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives.

Authors:  J R Docherty; A R Green
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

7.  Incidental use of ecstasy: no evidence for harmful effects on cognitive brain function in a prospective fMRI study.

Authors:  Gerry Jager; Maartje M de Win; Hylke K Vervaeke; Thelma Schilt; Rene S Kahn; Wim van den Brink; Jan M van Ree; Nick F Ramsey
Journal:  Psychopharmacology (Berl)       Date:  2007-05-03       Impact factor: 4.530

Review 8.  Abuse of amphetamines and structural abnormalities in the brain.

Authors:  Steven Berman; Joseph O'Neill; Scott Fears; George Bartzokis; Edythe D London
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

Review 9.  Role of the serotonin 5-HT(2A) receptor in learning.

Authors:  John A Harvey
Journal:  Learn Mem       Date:  2003 Sep-Oct       Impact factor: 2.460

10.  Tri-city study of Ecstasy use problems: a latent class analysis.

Authors:  Lawrence M Scheier; Arbi Ben Abdallah; James A Inciardi; Jan Copeland; Linda B Cottler
Journal:  Drug Alcohol Depend       Date:  2008-07-31       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.